论文部分内容阅读
由于肥胖症和2型糖尿病患者越来越多,非酒精性脂肪性肝病(NAFLD)也呈现逐年上升趋势。NAFLD可引起肝硬化和肝癌等并发症,严重威胁公众健康,目前尚无有效治疗NAFLD及其并发症的药物。肝脏甘油三酯聚集是NAFLD的重要标志,过氧化物酶体增殖物活化受体(PPAR)可参与脂代谢、糖代谢以及炎症的调控。本文综述了PPAR参与NAFLD的可能作用机制以及治疗NAFLD的PPAR激动剂的研究进展。
Due to the increasing number of obese and type 2 diabetic patients, non-alcoholic fatty liver disease (NAFLD) also shows a year-by-year upward trend. NAFLD can cause complications such as liver cirrhosis and liver cancer, a serious threat to public health, there is no effective treatment of NAFLD and its complications of drugs. Hepatic triglyceride aggregation is an important marker of NAFLD. Peroxisome proliferator-activated receptor (PPAR) is involved in the regulation of lipid metabolism, glucose metabolism and inflammation. This review summarizes the possible mechanism of PPAR involved in NAFLD and the progress of PPAR agonists in the treatment of NAFLD.